Ascelia Pharma AB (OSTO:ACE) Moat Score: 0/10 (As of Jun. 30, 2026)


OSTO:ACE Ascelia Pharma AB OSTO:ACE
29 GF Score
Price kr2.93
! 1 Warning Sign
View Full Analysis

What is Ascelia Pharma AB Moat Score?

Ascelia Pharma AB has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Ascelia Pharma AB has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Ascelia Pharma AB might have No Moat - No discernible moat.

Ascelia Pharma AB  (OSTO:ACE) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Ascelia Pharma AB Moat Score Related Terms

OSTO:ACE
29GF Score
Ascelia Pharma AB OSTO:ACE
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ascelia Pharma AB Business Description

Other Exchanges ACEs:UK
Address Hyllie Boulevard 34, Malmo, SWE, 215 32
Ascelia Pharma AB is a biotech company focused on orphan oncology treatments. The company develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. It has two drug candidates, Orviglance and Oncoral, in development. Orviglance (manganese chloride tetrahydrate) is an oral contrast agent for MR imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with impaired kidney function, and Oncoral is a novel oral irinotecan tablet in development.
29GF Score

Get the complete analysis for OSTO:ACE

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr2.93
Price